Nijmegen, the Netherlands-based Plasmacure, a developer of the PLASOMA cold plasma system for complex wound treatment, has secured €6M funding in a Series A investment from a strategic consortium led by U.S.-based Venture Medical.
Venture Medical is a U.S.-based healthcare services company with over 15 years of experience in advanced wound care and healing.
It operates as a master distributor, reseller, and digital solutions provider, serving healthcare manufacturers and end-users across biologics, diagnostics, DME, and capital equipment sectors.
In addition to the direct investment, Venture Medical will spearhead financing for regulatory approval and reimbursement in the United States, with total U.S. go-to-market support expected to exceed $10M (approximately €8.5M).
The funding consortium also includes Dutch health insurer Coöperatie VGZ, impact investor Noaber, and Stichting Triade, alongside existing shareholders EIC Fund and Oost NL.
Fund utilisation
This investment will allow Plasmacure to expand globally and promote the adoption of PLASOMA as an advanced solution for complex wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
“We are deeply motivated by the needs of the millions living with hard-to-heal wounds,” says Bjorn Sprengers, CEO of Plasmacure. “With this investment and our new strategic partners, we are in a strong position to bring PLASOMA to more patients worldwide. Our vision is to transform wound care; improve outcomes and give patients back their mobility, dignity, and freedom. With PLASOMA, we aim to set a new global standard in the treatment of complex wounds.”
What does Plasmacure solve?
As the global population ages and diabetes rates rise, about 5 per cent of elderly people develop complex wounds. These wounds can greatly affect their quality of life and may lead to amputations.
Current treatments often do not work well, leading to ongoing issues and making up about 2–4 per cent of total healthcare costs.
A recent study found that PLASOMA can close up to 2.5 times more complex wounds than standard treatments.
Led by Bjorn Sprengers, Plasmacure is the developer of the PLASOMA cold plasma system for complex wound treatment.
Its flagship product, PLASOMA, applies cold plasma to accelerate healing in complex wounds, demonstrating up to 2.5 times greater effectiveness than standard care.
Cold plasma is created by energising gas molecules, producing a highly effective antimicrobial agent capable of eliminating even antibiotic-resistant bacteria.
It also stimulates blood flow and cell regeneration.
The PLASOMA pulser delivers controlled electric pulses to a disposable pad, generating cold plasma directly in the wound.
This safely initiates multiple healing mechanisms, accelerating recovery and reducing the burden of chronic wounds.
“We see PLASOMA as a transformative technology that redefines what’s possible in wound healing. By investing in Plasmacure and supporting its U.S. rollout, we are enabling clinicians to offer next-generation care that is both innovative and accessible,” says John Schroeder, CEO of Venture Medical.
01
From telecom veteran to Dutch Startup Visa success: The Jignesh Dave story